Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
NCT05735184
Recruiting
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
Register for Updates
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
NCT05654506
Recruiting
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Proliferative Glomerulonephritis With Monoclonal IgG Deposits
Register for Updates
OssDsign® Spine Registry Study ("Propel")
NCT05329129
Recruiting
The purpose of this multi-center, prospective, observational registry is to gather information on the clinical outcomes and real-world use of commercially available bone graft substitutes manufactured by OssDsign® AB, in patients who require spine fusion.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/03/2025
Locations: Twin Cities Orthopedics, Edina, Minnesota
Conditions: Degenerative Disc Disease, Spinal Stenosis
Register for Updates
Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock
NCT05298124
Recruiting
Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock. This study will be a multicenter, open-label, randomized-controlled... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cardiogenic Shock, Mitral Regurgitation
Register for Updates
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT03251118
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/03/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Register for Updates
Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases
NCT06870253
Recruiting
The goal of this observational study is to learn about the performance of the Bladder CARE™ Assay in patients suspected of having bladder cancer with atypical cytology or equivocal cystoscopy results. The main question it aims to answer is: • Does the Bladder CARE™ Assay detect bladder cancer in patients who have inconclusive cytology or cystoscopy results? Participants will provide one voided urine specimen on the day of, and prior to, the routine, scheduled standard of care initial or repeat... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/02/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Bladder Cancer, Urothelial Carcinoma Bladder
Register for Updates
Treatment of Upper Gastrointestinal Symptoms Using Hypnotherapy Sessions
NCT06846359
Recruiting
The purpose of this research is to evaluate if hypnotherapy delivered digitally will help your GI symptoms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: GI Symptoms
Register for Updates
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
NCT06770049
Recruiting
The purpose of this study is to develop an evidence-based precision medicine approach for obesity that enhances weight loss and promotes weight loss maintenance.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/02/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Obesity
Register for Updates
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
NCT06452316
Recruiting
This study will enroll subjects with qualifying limbal stem cell deficiency (LSCD). All subjects will receive CSB-001 investigational drug in either one or both study eyes. The study is comprised of two identical phases (Dosing Phase I and II) of test article dosing separated by a 31- to 40-day period, the Dosing Holiday, where no test article is administered. Dosing Phase II is followed by an observational, noninterventional phase (Observation Phase).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Minnesota Eye Consultants, Minnetonka, Minnesota
Conditions: Limbal Stem Cell Deficiency
Register for Updates
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
NCT05928390
Recruiting
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Mayo Clinic - Rochester, 200 First Street, SW, 55905, Rochester, Minnesota
Conditions: Post-Bariatric Hypoglycemia
Register for Updates
CONVERGE Post-Approval Study (PAS)
NCT05393180
Recruiting
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/02/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Chronic Atrial Fibrillation
Register for Updates
Emicizumab in Patients With Acquired Hemophilia A
NCT05345197
Recruiting
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Acquired Hemophilia A
Register for Updates